NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down

Zacks
Öffnen unter Zacks
NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down

Nektar Therapeutics NKTR reported a loss of $1.63 per share for the third quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $2.16. The company had incurred a loss of $1.87 per share in the year-ago quarter.

Total revenues in the third quarter came in at $9.4 million, down 20.4% year over year. The reported figure missed the Zacks Consensus Estimate of $10 million.

Nektar sold its Huntsville manufacturing facility in December 2024, following which the company no longer records product revenues and lower non-cash royalty revenues. The company’s top line currently comprises non-cash royalty revenues.

Shares of Nektar fell 4.5% in after-hours trading on Thursday following the announcement of mixed third-quarter 2026 results and a reduction in its full-year 2026 revenue guidance.

Year to date, shares of Nektar have plunged 11.9% against the industry’s rise of 0.6%.

Zacks Investment Research
Image Source: Zacks Investment Research

NKTR's Q3 Results in Detail

In the third quarter, R&D expenses were $44.1 million, up 61.9% year over year. The increase reflected higher costs associated with the phase III ZENITH AD and ZENITH AA programs, along with manufacturing activities related to rezpeg.

General and administrative (G&A) expenses increased 52.9% year over year to $24.6 million, primarily due to higher legal expenses.

As of Sept. 30, 2026, Nektar had cash, cash equivalents and marketable securities worth $952.9 million compared with $1.02 billion as of June 30, 2026.

NKTR 2026 Guidance

Nektar now expects non-cash royalty revenues of approximately $38 million in 2026, down from its previous guidance of $40-$45 million.

R&D expenses for 2026 are now expected to be between $185 million and $200 million, lower than the previously projected $210-$230 million. The updated guidance includes approximately $5-$10 million of non-cash depreciation and stock-based compensation expenses.

G&A expenses are anticipated to be approximately $65 million, including around $5 million in non-cash expenses. NKTR expects to end 2026 with more than $840 million in cash.

NKTR's Key Pipeline Updates

Nektar's lead pipeline candidate, rezpeg, is being developed as a self-administered injection for several autoimmune and inflammatory diseases. Rezpeg selectively activates regulatory T-cells to calm the immune system and reduce inflammation.

All three phase III studies under the ZENITH AD program have now been initiated. ZENITH AD-1 evaluates rezpeg in treatment-naive patients, while ZENITH AD-3 focuses on patients previously treated with biologics or JAK inhibitors.

Following regulatory feedback, ZENITH AD-2 was modified to evaluate rezpeg in combination with topical corticosteroids in both treatment-naive and experienced patients.

Initial top-line data from the ZENITH AD program are expected to be announced in the summer of 2028. If successful, the company expects to file a biologics license application for rezpeg to treat moderate-to-severe atopic dermatitis by the end of 2029.

Beyond atopic dermatitis, rezpeg is being developed for alopecia areata. Nektar plans to initiate the phase III ZENITH AA study in December 2026, earlier than previously anticipated. Data are expected in 2029.

Meanwhile, Nektar plans to initiate a proof-of-concept study evaluating rezpeg in approximately 30 patients with vitiligo. Initial data are expected in late 2027 or early 2028.

The TrialNet-sponsored phase II study evaluating rezpeg in patients with new-onset type I diabetes is also ongoing. Initial cohort data are anticipated in late 2027 or early 2028.

Nektar regained full rights to rezpeg from pharma giant Eli Lilly LLY in April 2023 and took charge of its clinical development. Rezpeg was earlier developed in collaboration with LLY for several autoimmune indications.

Rezpeg is now a wholly-owned asset of Nektar, and the company owes no royalty payments to Eli Lilly.

Nektar Therapeutics Price, Consensus and EPS Surprise

Nektar Therapeutics Price, Consensus and EPS Surprise

Nektar Therapeutics price-consensus-eps-surprise-chart | Nektar Therapeutics Quote

NKTR's Zacks Rank & Other Stock to Consider

Nektar currently carries a Zacks Rank #2 (Buy).

A top-ranked stock in the drug sector is Collegium Pharmaceutical COLL, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, estimates for Collegium Pharmaceutical’s 2026 earnings per share have risen from $7.15 to $7.39, while estimates for 2027 have increased from $5.75 to $6.84 during the same time. COLL shares have plunged 46.1% year to date.

Collegium Pharmaceutical’s earnings beat estimates in three of the trailing four quarters, while missing estimates on the remaining occasion, with the average surprise being 10.53%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Nektar Therapeutics (NKTR): Free Stock Analysis Report
 
Eli Lilly and Company (LLY): Free Stock Analysis Report
 
Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research